Aberdeen Group plc Sells 9,856 Shares of Integer Holdings Corporation $ITGR

Key Points

• Aberdeen Group plc reduced its stake in Integer Holdings Corporation by 4.1%, owning 230,445 shares valued at approximately $27.2 million as of the end of the first quarter.
• Analysts have varying ratings for Integer, with Benchmark lowering its price target to $140 while Citigroup upgraded it to a "strong-buy" with a target of $140.
• Integer reported earnings of $1.55 per share, slightly missing expectations, but its revenue increased by 11.4% compared to the same quarter last year.

Aberdeen Group plc lowered its stake in Integer Holdings Corporation (NYSE:ITGR - Free Report) by 4.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 230,445 shares of the medical equipment provider's stock after selling 9,856 shares during the period. Aberdeen Group plc owned 0.66% of Integer worth $27,195,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Integer in the fourth quarter worth $208,000. Teacher Retirement System of Texas acquired a new position in Integer during the 1st quarter worth about $579,000. Northern Trust Corp grew its position in shares of Integer by 14.2% in the 4th quarter. Northern Trust Corp now owns 422,380 shares of the medical equipment provider's stock valued at $55,974,000 after buying an additional 52,556 shares during the last quarter. MQS Management LLC acquired a new stake in shares of Integer in the first quarter valued at about $272,000. Finally, Sterling Capital Management LLC raised its position in shares of Integer by 472.9% during the fourth quarter. Sterling Capital Management LLC now owns 338 shares of the medical equipment provider's stock worth $45,000 after acquiring an additional 279 shares during the last quarter. Institutional investors and hedge funds own 99.29% of the company's stock.

Integer Stock Up 3.3%

Shares of NYSE:ITGR traded up $3.5050 during trading on Friday, reaching $110.3350. 60,437 shares of the stock traded hands, compared to its average volume of 478,587. The stock has a market cap of $3.87 billion, a P/E ratio of 48.61, a price-to-earnings-growth ratio of 0.85 and a beta of 1.02. The stock has a 50-day moving average of $113.91 and a two-hundred day moving average of $119.40. Integer Holdings Corporation has a 52-week low of $104.93 and a 52-week high of $146.36. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.18 and a current ratio of 3.41.

Integer (NYSE:ITGR - Get Free Report) last posted its quarterly earnings results on Thursday, July 24th. The medical equipment provider reported $1.55 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.02). Integer had a return on equity of 12.27% and a net margin of 4.61%.The business had revenue of $476.00 million during the quarter, compared to analysts' expectations of $464.37 million. During the same quarter in the prior year, the firm earned $1.30 EPS. The firm's revenue for the quarter was up 11.4% compared to the same quarter last year. Integer has set its FY 2025 guidance at 6.250-6.510 EPS. As a group, sell-side analysts expect that Integer Holdings Corporation will post 6.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ITGR has been the topic of several recent analyst reports. Wall Street Zen upgraded shares of Integer from a "sell" rating to a "hold" rating in a report on Monday, May 19th. Benchmark reduced their price objective on Integer from $150.00 to $140.00 and set a "buy" rating for the company in a report on Friday, April 25th. Raymond James Financial cut their price objective on shares of Integer from $150.00 to $143.00 and set an "outperform" rating for the company in a research report on Friday, July 25th. Citigroup upgraded shares of Integer from a "hold" rating to a "strong-buy" rating and raised their price objective for the company from $133.00 to $140.00 in a research report on Thursday, May 22nd. Finally, Wells Fargo & Company cut their price objective on shares of Integer from $152.00 to $132.00 and set an "overweight" rating for the company in a research note on Friday, July 25th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $140.25.

Insider Buying and Selling at Integer

In other Integer news, Director Donald J. Spence sold 14,739 shares of the stock in a transaction on Wednesday, June 4th. The stock was sold at an average price of $120.38, for a total value of $1,774,280.82. Following the completion of the sale, the director owned 18,781 shares in the company, valued at approximately $2,260,856.78. This represents a 43.97% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Martin C. Maxwell sold 8,720 shares of the business's stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $120.56, for a total value of $1,051,283.20. Following the completion of the transaction, the director directly owned 22,170 shares in the company, valued at approximately $2,672,815.20. This represents a 28.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.16% of the company's stock.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.